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Increasing evidence suggests that lead exposure
may contribute to decreased renal function
(Kim et al. 1996; Lin et al. 1999, 2003;
Muntner et al. 2003; Payton et al. 1994;
Staessen et al. 1992; Yu et al. 2004) and
increased uric acid levels (Lin et al. 2002,
2001; Shadick et al. 2000) at lower doses than
previously recognized, particularly in suscepti-
ble populations. Similarly, an increasing body
of literature suggests that uric acid may be
nephrotoxic at lower levels than currently
appreciated (Johnson et al. 2003). In previous
analyses in the same population of lead work-
ers reported here, we found associations
between lead dose and increased uric acid in
older workers and evidence that uric acid may
mediate some lead-related adverse renal effects
(Weaver et al. 2005). Therefore, to understand
the mechanisms of lead-related nephrotoxicity,
it would be helpful to determine whether
genetic polymorphisms that are associated with
renal outcomes in lead workers and/or modify
associations between lead dose and renal func-
tion are also associated with uric acid and/or
modify associations between lead dose and uric
acid. In this study we evaluated three such
genetic polymorphisms: δ-aminolevulinic acid
dehydratase (ALAD), the BsmI polymorphism
of the vitamin D receptor (VDR) gene, and the
Glu298Asp polymorphism of the endothelial
nitric oxide synthase (eNOS) gene. We exam-
ined associations of these polymorphisms and
their effect modification on associations of
three lead dose biomarkers in models of uric
acid in a cross-sectional analysis of data from
the ﬁrst of three evaluations of 798 current and
former Korean lead workers in a longitudinal
study of the adverse health effects of inorganic
lead exposure.
Materials and Methods
Study design and population. We performed
a cross-sectional analysis of first evaluation
data from 798 current and former lead work-
ers enrolled in a longitudinal study of the
adverse health effects of inorganic lead expo-
sure. All participants provided written,
informed consent. The study protocol was
approved by institutional review boards at the
SoonChunHyang University and the Johns
Hopkins University Bloomberg School of
Public Health. Participation in the study was
voluntary, and workers were paid approxi-
mately $30 for their time and effort. As previ-
ously described (Schwartz et al. 2001; Weaver
et al. 2003a), workers were recruited from
26 different facilities including lead battery,
lead oxide, lead crystal, and radiator manufac-
tures and secondary lead smelting. No medi-
cal exclusionary criteria (e.g., blood pressure,
renal disease) were applied. Study participants
were not currently occupationally exposed to
other known renal toxicants.
Data collection. Data collection was com-
pleted either at the Institute of Industrial
Medicine of the SoonChunHyang University
in Chonan or at the study plants, using previ-
ously reported methods (Schwartz et al. 2001;
Weaver et al. 2003a). Data and biologic spec-
imens collected included a standardized ques-
tionnaire on demographics and medical and
occupational history; blood pressure; height
and weight measurement; a blood specimen
[for blood lead, blood urea nitrogen (BUN),
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Recent research suggests that uric acid may be nephrotoxic at lower levels than previously recog-
nized and that it may be one mechanism for lead-related nephrotoxicity. Therefore, in under-
standing mechanisms for lead-related nephrotoxicity, it would be of value to determine whether
genetic polymorphisms that are associated with renal outcomes in lead workers and/or modify
associations between lead dose and renal function are also associated with uric acid and/or modify
associations between lead dose and uric acid. We analyzed data on three such genetic polymor-
phisms: δ-aminolevulinic acid dehydratase (ALAD), endothelial nitric oxide synthase (eNOS), and
the vitamin D receptor (VDR). Mean (± SD) tibia, blood, and dimercaptosuccinic acid–chelatable
lead levels were 37.2 ± 40.4 µg/g bone mineral, 32.0± 15.0 g/dL, and 0.77± 0.86 µg/mg creati-
nine, respectively, in 798 current and former lead workers. Participants with the eNOS Asp allele
had lower mean serum uric acid compared with those with the Glu/Glu genotype. Among older
workers (age ≥ median of 40.6 years), ALAD genotype modified associations between lead dose
and uric acid levels. Higher lead dose was signiﬁcantly associated with higher uric acid in workers
with the ALAD1-1 genotype; associations were in the opposite direction in participants with the
variant ALAD1-2 genotype. In contrast, higher tibia lead was associated with higher uric acid in
those with the variant VDR B allele; however, modiﬁcation was dependent on participants with the
bb genotype and high tibia lead levels. We conclude that genetic polymorphisms may modify uric
acid mediation of lead-related adverse renal effects. Key words: δ-aminolevulinic acid dehydratase,
endothelial nitric oxide synthase, genetic susceptibility factors, kidney function, lead exposure, uric
acid, vitamin D receptor. Environ Health Perspect 113:1509–1515 (2005). doi:10.1289/ehp.7927
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a spot urine sample [for N-acetyl-β-D-glu-
cosaminidase (NAG), retinol-binding protein
(RBP), and creatinine]; and tibia lead concen-
tration. A 4-hr urine collection after oral
administration of 10 mg/kg dimercapto-
succinic acid (DMSA) was also obtained to
measure DMSA-chelatable lead and creati-
nine clearance (787 participants completed
this collection).
Laboratory methods. We measured lead
biomarkers and renal outcomes using previ-
ously reported methods (Schwartz et al. 2001;
Weaver et al. 2003a). In brief, blood lead was
measured (Fernandez 1975) with a Zeeman
background-corrected atomic absorption
spectrophotometer (model 8100; Hitachi
Ltd. Instruments, Tokyo, Japan) at the
Institute of Industrial Medicine, a certified
reference laboratory for lead in Korea. Tibia
lead was assessed via a 30-min measurement
of the left midtibia diaphysis using 109Cd to
ﬂuoresce the K-shell X-rays of lead. The lead
X-rays were recorded with a radiation detec-
tor and then quantified and compared with
calibration data to estimate the concentration
of lead in bone (Todd and Chettle 1994;
Todd and McNeill 1993). All point estimates,
including negative values, were retained in the
statistical analyses, to minimize bias and to
avoid censoring of data (Kim et al. 1995).
Urine lead levels in the 4-hr collection were
measured at the Wadsworth Center of the
New York State Department of Health
(Albany, NY, USA) by electrothermal atomic
absorption spectrometry with Zeeman back-
ground correction (model 4100ZL; Perkin-
Elmer, Norwalk, CT, USA) (Parsons and
Slavin 1999).
We measured BUN, serum creatinine,
and uric acid using an automatic chemical
analyzer (model TBA 40FR biochemical ana-
lyzer; Toshiba, Tokyo, Japan). Urine creati-
nine was measured with the Sigma kit (Sigma
Chemical Company, St. Louis, MO, USA).
Measured creatinine clearance was deﬁned as
[(urinary creatinine in milligrams per deciliter
× urine volume in milliliters) ÷ serum creati-
nine in milligrams per deciliter] ÷ collection
time in minutes. Calculated creatinine clear-
ance was obtained from the Cockcroft-Gault
equation (Cockcroft and Gault 1976). We
measured NAG using the PPR NAG test kit
(PPR Diagnostics, Ltd., London, UK), and
RBP was measured using a modification of
the method of Topping et al. (1986).
We isolated DNA for genotyping from
whole blood samples using the QIAamp blood
kit (QIAGEN, Hilden, Germany). The ALAD
polymorphism assayed (δ-aminolevulinic acid
dehydratase NCBI accession no. AY319481)
results in two alleles: ALAD1 and the variant,
ALAD2, which has a G-to-C transversion at
codon 177. The protocol for ALAD genotyp-
ing involved an initial ampliﬁcation that gener-
ated a 916 bp fragment (Schwartz et al. 1995;
Wetmur et al. 1991; Ziemsen et al. 1986). A
second amplification, using a pair of nested
primers (kindly provided by J. Wetmur), gen-
erated an 887 bp fragment. The ampliﬁed frag-
ment was cleaved at the diagnostic Msp1 site
on the ALAD2 allele. The Glu298Asp poly-
morphism of the eNOS gene (endothelial nitric
oxidase synthase; NCBI accession no. X76307)
involves a G-to-T transversion at nucleotide
position 894 within exon 7, which results in
substitution of aspartic acid for glutamic acid
at codon 298; the variant allele is referred to as
the Asp or T allele. Genotype was determined
by a modification of the assay of Hibi et al.
(1998) as previously described (Weaver et al.
2003b). The VDR BsmI polymorphic site in
intron 8 [vitamin D (1,25-dihydroxyvitamin
D3) receptor; NCBI accession no. AY342401]
Weaver et al.
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Table 1. Selected demographic, exposure, and outcome variables by ALAD, eNOS, and VDR genotype in 798 Korean lead workers.a
ALAD eNOS VDR
Characteristic 1-1 1-2 Glu/Glu Asp/Glu or Asp/Asp bb Bb or BB
No. (%) 716 (90.1) 79 (9.9) 673 (84.9) 120 (15.1) 709 (88.8) 89 (11.2)
Sex n (%)
Male 569 (79.5) 62 (78.5) 537 (79.8) 93 (77.5) 572 (80.7) 62 (69.7)
Female 147 (20.5) 17 (21.5) 136 (20.2) 27 (22.5) 137 (19.3) 27 (30.3)
Alcohol use, n (%)
No previous alcohol 207 (29.0) 24 (30.4) 201 (30.0) 30 (25.0) 208 (29.4) 23 (25.8)
Current use 466 (65.2) 49 (62.0) 429 (63.8) 84 (70.0) 456 (64.4) 62 (69.7)
Past use 42 (5.9) 6 (7.6) 42 (6.3) 6 (5.0) 44 (6.2) 4 (4.5)
BMI (kg/m2) 23.1 ± 3.0 22.3 ± 2.6 23.1 ± 3.0 22.7 ± 2.8 22.9 ± 2.9 23.9 ± 3.4
Age (years) 40.5 ± 10.2 40.1 ± 9.7 40.3 ± 10.1 41.1 ± 10.1 40.2 ± 10.1 42.7 ± 10.3
Systolic blood pressure (mm Hg) 123.4 ± 16.5 122.3 ± 14.5 123.4 ± 16.5 122.7 ± 15.5 122.6 ± 15.6 129.1 ± 20.6
Blood lead (µg/dL) 31.7 ± 14.9 34.2 ± 15.9 32.0 ± 15.1 31.2 ± 14.6 31.6 ± 14.8 34.8 ± 16.1
Tibia lead (µg Pb/g bone mineral) 37.5 ± 40.6 31.4 ± 29.5 37.5 ± 41.6 35.8 ± 34.0 37.1 ± 41.2 38.1 ± 33.5
DMSA-chelatable lead (µg Pb/mg creatinine) 0.76 ± 0.82 0.84 ± 1.19 0.78 ± 0.90 0.72 ± 0.62 0.75 ± 0.87 0.93 ± 0.76
Uric acid (mg/dL) 4.8 ± 1.2 4.6 ± 1.1 4.9 ± 1.2 4.6 ± 1.1 4.8 ± 1.2 4.7 ± 1.1
Serum creatinine (mg/dL) 0.90 ± 0.15 0.86 ± 0.12 0.90 ± 0.16 0.89 ± 0.13 0.90 ± 0.16 0.89 ± 0.13
ALAD, eNOS, and VDR genotyping were completed on 795, 793, and 798 lead workers, respectively. Modiﬁed from Weaver et al. (2003b).
aValues are mean ± SD unless otherwise noted. 
Table 2. Medians of selected demographic, exposure, and outcome variables in Korean lead workers by ALAD and VDR genotype in two groups dichotomized by
median age (40.6 years).
ALAD VDR
Age < 40.6 years Age ≥ 40.6 years Age < 40.6 years Age ≥ 40.6 years
Characteristic 1-1 1-2 1-1 1-2 bb Bb or BB bb Bb or BB
No.a 355 42 361 37 360 38 349 51
Age (years) 32.8 33.3 48.6 49.4 32.7 33.7 48.3 49.7
Lead job duration (years) 3.9 4.1 9.7 9.5 3.8 4.2 9.8 8.3
Blood lead (µg/dL) 28.8 31.9 30.4 34.3 29.5 29.4 30.4 35.5
Tibia lead (µg Pb/g bone mineral) 20.9 22.1 30.7 25.6 20.9 25.4 29.4 35.1
DMSA-chelatable lead (µg Pb/mg creatinine) 0.39 0.54 0.64 0.64 0.39 0.60 0.62 0.82
Uric acid (mg/dL) 5.1 4.9 4.4 4.1 5.1 5.2 4.4 4.2
BUN (mg/dL) 13.9 12.4 14.4 13.7 13.7 13.1 14.4 14.0
Serum creatinine (mg/dL) 0.93 0.89 0.88 0.81 0.92 0.91 0.87 0.86
Measured creatinine clearance (mL/min) 121.8 119.0 101.4 108.9 121.5 118.1 103.3 100.6
Calculated creatinine clearance (mL/min) 102.9 102.0 83.4 85.4 102.8 101.6 83.6 83.1
aActual value, not median.consists of the common allele, denoted b, and a
variant, denoted B, in which the BsmI restric-
tion enzyme site is absent. Ampliﬁcation used
primers originating in exon 7 and intron 8 as
previously published (Schwartz et al. 2000b).
Statistical analysis. The primary goals of
our analysis were to examine associations of
ALAD, VDR, and eNOS genotype with uric
acid in lead workers while controlling for
other covariates and to evaluate whether
ALAD, VDR, and eNOS genotypes modiﬁed
associations between the lead dose biomarkers
(tibia lead, blood lead, DMSA-chelatable
lead) and uric acid while controlling for other
covariates. Statistical analysis was completed
using SAS software, version 8.2 (SAS Institute,
Cary, NC, USA). 
Initially, we examined variable distribu-
tions. The distributions of NAG and RBP
showed departures from normality and were
thus ln-transformed; the adequacy of this
transformation was subsequently conﬁrmed by
examination of residuals from the ﬁnal regres-
sion models. Linear regression modeling with a
dichotomous genotype variable was used to
compare uric acid by genotype, while control-
ling for the same covariates used in the interac-
tion models. For ALAD, participants with the
ALAD1-2 genotype were compared with the
reference group of participants with ALAD1-1
genotype. Because of small numbers, all analy-
ses combined homozygous and heterozygous
variant genotype carriers for VDR (BB and Bb)
and eNOS (Glu/Asp and Asp/Asp). Linear
regression modeling with genotype and lead
variable cross-product terms was used to evalu-
ate effect modiﬁcation by genotype on associa-
tions between lead biomarkers and uric acid.
Models with tibia lead were repeated after
removal of data from participants with the
common allele whose tibia lead levels were
higher than the range in those with the variant
allele. Covariate selection for final regression
models used a priori variables [age, sex, body
mass index (BMI; defined as weight in kilo-
grams divided by the square of height in
meters)] in modeling that included other bio-
logically relevant variables in separate models, as
previously described (Weaver et al. 2005).
Covariates retained included age, sex, BMI, cat-
egorical alcohol consumption (current, former,
never), and, when noted in speciﬁc models, sys-
tolic blood pressure and serum creatinine.
Models are presented with and without these
last two variables because their interrelatedness
with lead dose and uric acid suggests that nei-
ther modeling approach is entirely adequate
(Weaver et al. 2005). Continuous independent
variables were centered at the mean.
Because effect modiﬁcation by age on asso-
ciations between lead biomarkers and uric acid
was observed in this population (Weaver et al.
2005), we dichotomized the population by
median age and repeated both types of models
described above (main effect and interaction) to
evaluate associations of genotype in models of
uric acid and effect modiﬁcation by genotype
on associations between lead biomarkers and
uric acid in different age groups. Last, a model
that included cross-products of tibia lead and
combined ALAD/VDR genotype subsets was
evaluated in participants in the older half of the
population to determine if the genotype associ-
ation previously reported in this population
(lead workers with the ALAD1-1 genotype were
statistically less likely to have the VDR bb geno-
type; Schwartz et al. 2000a) was a factor in the
effect modiﬁcation observed in this study. Only
two participants in the older age group had
both variant alleles (ALAD1-2/VDR Bb or BB),
which precluded meaningful analysis of this
group; this subset was removed from the
model. The ﬁnal model assessed differences in
the slopes of the relations between tibia lead
and uric acid in the group of participants with
the ALAD1-2/VDR bb genotypes and the
ALAD1-1/VDR Bb or BB genotypes, in sepa-
rate cross-product terms, compared with the
reference group of participants with the
ALAD1-1 and VDR bb genotypes.
As in previous analyses (Weaver et al.
2003a), we evaluated models for linear regres-
sion assumptions and the presence of outlying
points using added variable plots (Weisberg
1985), which are graphical summaries of the
relation between y and a particular x adjusted
for the other covariates. For each plot, two
lines were overlaid: the regression line, and a
line determined by a scatter plot smoothing
method (lowess) that calculates a locally
weighted least squares estimate for each point
in the scatter plot (Cleveland 1979). This
Uric acid and gene polymorphisms in lead workers
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Table 3. Linear regression models of uric acid, evaluating effect modification by ALAD genotype on associations of blood and tibia lead in two groups of lead
workers, dichotomized by median age (40.6 years).
Panel 1: age < 40.6 years Panel 2: age ≥ 40.6 years Panel 3: age ≥ 40.6 years
Variable β-Coefﬁcient SE β p-Value β-Coefﬁcient SE β p-Value β-Coefﬁcient SE β p-Value
Blood lead models
Intercept 4.4070 0.1776 < 0.01 4.7507 0.1108 < 0.01 4.5906 0.1078 < 0.01
Age (years) –0.0348 0.0084 < 0.01 –0.0123 0.0098 0.21 –0.0188 0.0098 0.06
Systolic blood pressure (mm Hg) — — — — — — 0.0046 0.0027 0.09
Serum creatinine (mg/dL) — — — — — — 2.4921 0.3799 < 0.01
ALAD1-2 –0.2619 0.1591 0.10 –0.0292 0.1776 0.87 0.0870 0.1693 0.61
Blood lead (µg/dL)a –0.0043 0.0040 0.27 0.0127 0.0040 < 0.01 0.0089 0.0038 0.02
Blood lead × ALAD1-2b –0.0161 0.0134 0.23 –0.0212 0.0102 0.04 –0.0143 0.0098 0.14
Tibia lead models
Intercept 4.3928 0.1746 < 0.01 4.7280 0.1075 < 0.01 4.6027 0.1074 < 0.01
Age (years) –0.0335 0.0083 < 0.01 –0.0062 0.0096 0.52 –0.0157 0.0098 0.11
Systolic blood pressure (mm Hg) — — — — — — 0.0059 0.0027 0.03
Serum creatinine (mg/dL) — — — — — — 2.0767 0.4380 < 0.01
ALAD1-2 –0.3553 0.2330 0.13 –0.1993 0.2013 0.32 –0.1180 0.1955 0.55
Tibia lead (µg Pb/g bone mineral)a –0.0044 0.0020 0.03 0.0009 0.0013 0.48 0.0002 0.0013 0.89
Tibia lead × ALAD1-2b –0.0047 0.0103 0.65 –0.0151 0.0079 0.06 –0.0138 0.0077 0.07
Truncated tibia lead modelsc 
Intercept 4.8218 0.1159 < 0.01 4.6499 0.1159 < 0.01
Age (years) –0.0074 0.0103 0.48 –0.0160 0.0103 0.12
Systolic blood pressure (mm Hg) — — — 0.0058 0.0028 0.04
Serum creatinine (mg/dL) — — — 2.3661 0.4620 < 0.01
ALAD1-2 –0.2763 0.2110 0.19 –0.1737 0.2033 0.39
Tibia lead (µg Pb/g bone mineral)a 0.0079 0.0027 < 0.01 0.0063 0.0026 0.02
Tibia lead × ALAD1-2b –0.0214 0.0084 0.01 –0.0193 0.0080 0.02
—, model shown was not adjusted for that covariate. Panels 1 and 2 display results in the younger and older groups, respectively. Panel 3 shows results in the older group after additional con-
trol for systolic blood pressure and serum creatinine. Models were also adjusted for sex, BMI, and alcohol use. 
aReference category of homozygotes for the common gene allele (ALAD1-1). bp-Values for the cross-product terms reﬂect the statistical signiﬁcance of the difference between the slopes of
the regression line for the variant gene group and the regression line for the reference gene group; slopes in the variant gene group are obtained by adding the β-coefﬁcient of the cross-prod-
uct term to the β-coefﬁcient for the reference category [i.e., the slope of the relation between blood lead and uric acid in those with ALAD1-2 genotype is –0.0085 in panel 2 (0.0127 + –0.0212)].
cTibia lead levels > 89 µg Pb/g bone mineral were removed from models. allows an examination of the data for outliers
that are overly influential, as evidenced by
inconsistency between the lowess and regres-
sion lines. When warranted, models were
repeated without outliers. Models were also
assessed for collinearity by examining variance
inﬂation factors and conditional indices.
Results
Selected demographics, exposure, and health
outcome measures. A total of 79 (9.9%) par-
ticipants were heterozygous for the ALAD2
allele, and none was homozygous (Table 1).
For VDR, 85 (10.7%) were genotype Bb, and
4 (0.5%) were BB. For eNOS, 114 (14.4%)
participants were genotype Glu/Asp, and
6 (0.7%) were Asp/Asp. Mean (± SD) and fre-
quencies for selected demographic, exposure,
and outcome variables are presented by geno-
type in Table 1. Mean uric acid was normal
in all genotype subsets. Medians for selected
measures are presented by genotype in groups
dichotomized by median age (Table 2).
ALAD. Mean uric acid did not differ by
ALAD genotype in the total population or in
either age group (dichotomized by median age
of 40.6 years). Among all participants, ALAD
genotype modified the association between
blood lead and uric acid. β-Coefﬁcients were
0.0047 (p = 0.10) for blood lead in the
reference group of those with the ALAD1-1
genotype and –0.0158 (p = 0.05) for the cross-
product term of ALAD1-2 genotype and
blood lead, respectively (thus, the slope of the
relation between blood lead and uric acid in
participants with the ALAD1-2 genotype was
–0.0111). This effect was conﬁned to workers
at or above the median age (Table 3, panels 1
and 2, blood lead models). The inverse nature
of these associations by genotype, from the
blood lead model in panel 2 of Table 3, is
shown graphically in Figure 1. Borderline
effect modiﬁcation on the association between
tibia lead and uric acid was also observed in
older participants (Table 3, panel 2, tibia lead
models). Consistent with known mechanisms
for the hyperuricemic effects of lead (Weaver
et al. 2005), β-coefficients decreased after
additional adjustment for blood pressure and
renal function (Table 3, panel 3). Results were
similar when calculated creatinine clearance
was added to these models instead of serum
creatinine (data not shown). Added variable
plots (Figure 2) of partial residuals of the tibia
lead model (Table 3, panel 2) suggested differ-
ent tibia lead level ranges by genotype. In
order to compare differences over a similar
range, data from 43 participants in the
ALAD1-1 group with tibia lead levels > 89 µg
Pb/g bone mineral (levels above the crude
range in participants with the ALAD1-2 geno-
type) were removed. A positive association
between tibia lead and uric acid in those with
the ALAD1-1 genotype (Table 3, truncated
tibia lead models, panel 2) was then observed.
VDR. Similar to ALAD, VDR genotype
was not associated with uric acid levels, and
effect modiﬁcation was conﬁned to older lead
workers (Table 4, tibia lead models, panels 1
and 2). However, in contrast to ALAD, tibia
lead was positively associated with uric acid in
those participants with the variant VDR B
allele, and effect modiﬁcation on associations
between blood lead and uric acid was not
observed (Table 4). Modeling that included
cross-products of tibia lead with combined
genotype subsets compared with a reference
group of participants with both the ALAD1-1
and VDR bb genotypes revealed that the
opposite direction associations between tibia
lead and uric acid in participants with the
VDR B allele compared with those with the
ALAD1-2 allele were not simply due to the
genotype associations previously reported in
this population (lead workers with the
ALAD1-1 genotype were statistically less
likely to have the VDR bb genotype; Schwartz
et al. 2000a) (Table 5). Similar to ALAD, the
range of tibia lead levels differed by genotype
(Figure 3). In contrast, when data from
27 participants with the VDR bb genotype
with tibia lead levels > 103 µg Pb/g bone
mineral (above the range in participants with
VDR Bb or BB genotypes) were removed in
order to compare differences over a similar
range, effect modiﬁcation was no longer sig-
niﬁcant (Table 4, truncated tibia lead models,
panel 2).
eNOS. In contrast to ALAD and VDR, the
eNOS genotype was associated with uric acid
levels. Mean serum uric acid was lower in par-
ticipants with the eNOS Asp allele compared
with those with the Glu/Glu genotype (β =
–0.1913; SE β = 0.0932; p = 0.04; adjusted for
age, sex, BMI, serum creatinine, systolic blood
pressure, and blood lead). Additional modeling
in two groups, dichotomized by median age,
revealed that this association was conﬁned to
participants in the older half of the population.
No effect modiﬁcation by eNOS genotype on
associations of lead biomarkers and uric acid
was observed.
Discussion
We evaluated whether polymorphisms in
three genes (ALAD, VDR, and eNOS) were
associated with uric acid or modiﬁed relations
of lead biomarkers with uric acid in a cross-
sectional analysis of data from the ﬁrst evalua-
tion in a longitudinal study of 798 current and
former Korean lead workers. After adjustment,
participants with the eNOS Asp allele had
lower mean uric acid. Effect modiﬁcation by
Weaver et al.
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Figure 2. Added variable plot of the model assessing effect modification by ALAD genotype on the
association between tibia lead and uric acid in Korean lead workers ≥ 40.6 years of age (Table 3, panel 2).
For each plot, the regression line (dashed line) and the lowess line (solid line) of the partial residual data
points, adjusted for age, sex, BMI, and alcohol use, are overlaid. For ease of interpretation, axes have
been scaled so that the plotted residuals are centered around mean uric acid and tibia lead, rather than
around zero.
Figure 1. Plot of model assessing effect modifica-
tion by ALAD genotype on the association of blood
lead and uric acid in Korean lead workers whose
ages are ≥ 40.6 years (Table 3, panel 2). Regression
lines, generated using mean values of covariates in
the model (age, sex, BMI, and alcohol use), are
overlaid on crude data. The solid regression line
represents the adjusted relation between blood
lead and uric acid in older participants with the
ALAD1-1 genotype (circles); the dashed regression
line represents the adjusted relation between
blood lead and uric acid in older participants with
the ALAD1-2 genotype (stars).
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ALAD1-1 ALAD1-2ALAD on associations between lead dose and
uric acid was observed in participants whose
ages were in the older half of the age range.
Higher lead dose was associated with higher
uric acid in workers with the ALAD1-1 geno-
type; associations were in the opposite direc-
tion in participants with the ALAD1-2
genotype. VDR genotype modiﬁed the associa-
tion of tibia lead and uric acid, also in the older
half of the population. However, in contrast to
ALAD, higher tibia lead was associated with
higher uric acid in those with the variant B
allele, but this effect was dependent on data
from participants with the bb genotype and
high tibia lead levels.
The ALAD enzyme is a principal lead-
binding protein. The isozymes in those with
the variant ALAD2 allele bind a greater pro-
portion of blood lead than does the isozyme in
individuals with the ALAD1-1 genotype
(Bergdahl et al. 1997). In the population that
is the focus of this report, mean blood lead
was higher in participants with the ALAD1-2
genotype compared with those with the
ALAD1-1 genotype (Schwartz et al. 2000a).
However, neither tibia nor DMSA-chelatable
lead levels differed signiﬁcantly. Other studies
have also reported that participants with the
ALAD2 allele have higher blood lead levels
than do those with the ALAD1-1 genotype,
although studies in populations with mean
blood lead levels < 10 µg/dL have generally
not reported a difference (Hu et al. 2001;
Kamel et al. 2003; Kelada et al. 2001). The
limited data on associations of ALAD geno-
type with bone lead levels reveal no difference
in some studies (similar to results in our popu-
lation) (Fleming et al. 1998; Smith et al.
1995). Lower cortical (tibia) and/or trabecular
(patella, calcaneus) bone lead levels in those
with the ALAD2 allele have been reported in
others (Hu et al. 2001; Kamel et al. 2003).
Other toxicokinetic differences have also been
reported in participants with the ALAD2 allele
(Fleming et al. 1998; Hu et al. 2001; Schwartz
et al. 1997; Smith et al. 1995). Overall, these
data suggest that tighter binding of lead by the
isozymes of the ALAD2 allele decreases lead
sequestration in bone. Therefore, the impact
on toxicity would depend on whether enzyme
bound lead is bioavailable and more toxic than
lead that is stored in bone and subsequently
released. As a result, toxicity may differ by tar-
get organ.
Two studies have examined the impact of
ALAD genotype on serum uric acid levels in
lead exposed populations. In a study of 691
construction workers, whose mean blood lead
was 7.8 µg/dL, Smith et al. (1995) found
borderline (p = 0.09) higher mean uric acid
after adjustment for age, alcohol ingestion,
and blood lead in the 96 participants with
the ALAD2 allele compared with those with
the ALAD1-1 genotype. Effect modification
was not evaluated. Wu et al. (2003) found no
Uric acid and gene polymorphisms in lead workers
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Table 4. Linear regression models of uric acid, evaluating effect modiﬁcation by VDR genotype on associations of blood and tibia lead in two groups of lead work-
ers, dichotomized by median age (40.6 years).
Panel 1: age < 40.6 years Panel 2: age ≥ 40.6 years Panel 3: age ≥ 40.6 years
β-Coefﬁcient SE β p-Value β-Coefﬁcient SE β p-Value β-Coefﬁcient SE β p-Value
Blood lead models
Intercept 4.3906 0.1754 < 0.01 4.7529 0.1104 < 0.01 4.6087 0.1074 < 0.01
Age (years) –0.0341 0.0083 < 0.01 –0.0118 0.0099 0.23 –0.0190 0.0099 0.06
Systolic blood pressure (mm Hg) —  — — — — — 0.0056 0.0027 0.04
Serum creatinine (mg/dL) — — — — — — 2.1009 0.3302 < 0.01
VDR Bb or BB 0.0073 0.1654 0.97 –0.0447 0.1565 0.78 –0.1201 0.1502 0.42
Blood lead (µg/dL)a –0.0056 0.0040 0.17 0.0111 0.0040 < 0.01 0.0087 0.0038 0.02
Blood lead × VDR Bb or BBb  0.0018 0.0109 0.87 –0.0041 0.0093 0.66 –0.0026 0.0089 0.77
Tibia lead models
Intercept 4.3660 0.1756 < 0.01 4.7474 0.1070 < 0.01 4.6267 0.1064 < 0.01
Age (years) –0.0338 0.0083 < 0.01 –0.0027 0.0097 0.78 –0.0122 0.0098 0.22
Systolic blood pressure (mm Hg) — — — — — — 0.0061 0.0027 0.02
Serum creatinine (mg/dL) — — — — — — 2.1603 0.4382 < 0.01
VDR Bb or BB –0.0599 0.2093 0.78 0.0842 0.1515 0.58 –0.0140 0.1484 0.93
Tibia lead (µg Pb/g bone mineral)a –0.0038 0.0021 0.07 –0.0008 0.0014 0.57 0.0015 0.0014 0.27
Tibia lead × VDR Bb or BBb  –0.0033 0.0083 0.69 0.0138 0.0062 0.03 0.0142 0.0060 0.02
Truncated tibia lead modelsc 
Intercept 4.7765 0.1110 < 0.01 4.6361 0.1108 < 0.01
Age (years) –0.0057 0.0101 0.57 –0.0142 0.0101 0.16
Systolic blood pressure (mm Hg) — — — 0.0061 0.0028 0.03
Serum creatinine (mg/dL) — — — 2.2604 0.4534 < 0.01
VDR Bb or BB 0.0502 0.1555 0.75 –0.0608 0.1522 0.69
Tibia lead (µg Pb/g bone mineral)a 0.0036 0.0023 0.12 0.0026 0.0022 0.26
Tibia lead × VDR Bb or BBb  0.0100 0.0064 0.12 0.0106 0.0062 0.09
—, model shown was not adjusted for that covariate. Panels 1 and 2 display results in the younger and older groups, respectively. Panel 3 shows results in the older group after addi-
tional control for systolic blood pressure and serum creatinine. Models were also adjusted for sex, BMI, and alcohol use. 
aReference category of homozygotes for the common gene allele (VDR bb). bp-Values for the cross-product terms reﬂect the statistical signiﬁcance of the difference between the slopes
of the regression line for the variant gene group and the regression line for the reference gene group; slopes in the variant gene group are obtained by adding the β-coefﬁcient of the
cross-product term to the β-coefﬁcient for the reference category [i.e., the slope of the relation between tibia lead and uric acid in those with VDR Bb or BB genotypes is 0.0130 in
panel 2 (–0.0008 + 0.0138)]. cTibia lead levels > 103 µg Pb/g bone mineral were removed from models.
Table 5. Linear regression model evaluating effect modiﬁcation by combined ALAD and VDR genotypes on
the association between tibia lead and uric acid, in lead workers ≥ 40.6 years of age (median).
Blood lead models β-Coefﬁcient SE β p-Value
Intercept 4.6078 0.1086 < 0.01
Age (years) –0.0133 0.0099 0.18
Systolic blood pressure (mm Hg) 0.0058 0.0027 0.03
Serum creatinine (mg/dL) 2.1352 0.4420 < 0.01
ALAD1-2 and VDR bb –0.1086 0.2067 0.60
ALAD1-1 and VDR Bb or BB 0.0111 0.1533 0.94
Tibia lead (µg Pb/g bone mineral)a –0.0008 0.0014 0.59
Tibia lead × ALAD1-2 and VDR bbb –0.0122 0.0079 0.12
Tibia lead × ALAD1-1 and VDR Bb or BBb 0.0140 0.0061 0.02
Models were also adjusted for sex, BMI, and alcohol use. 
aReference category for homozygotes for both common gene alleles (ALAD1-1 and VDR bb). bp-Values for the cross-prod-
uct terms reﬂect the statistical signiﬁcance of the difference between the slopes of the regression line for the variant gene
groups and the regression line for the reference gene group. Slopes in the variant gene groups are obtained by adding the
β-coefficient of the cross-product term to the β-coefficient for the reference category [i.e., the slope of the relation
between tibia lead and uric acid in those with both the ALAD1-1 and VDR Bb or BB genotypes is 0.0132 (–0.0008 + 0.0140)].difference in uric acid by genotype in 709 par-
ticipants in the Normative Aging Study (mean
blood lead = 6.2 µg/dL). However, effect mod-
iﬁcation by genotype on associations of patella
and tibia lead with uric acid of borderline sig-
niﬁcance (p < 0.1) was observed; β-coefﬁcients
(and slopes) were greater in those with the vari-
ant allele. This difference was significant in
participants whose patella lead levels were
> 15 µg/g bone mineral (p = 0.04).
Synthesizing our data with these studies is
complicated by the inverse associations we
observed. Similar inverse relations between
blood and DMSA-chelatable lead and renal
outcomes in participants with the ALAD2
allele were previously reported in this popula-
tion (Weaver et al. 2003b). Because uric acid is
ﬁltered at the glomerulus, levels in serum are
also inﬂuenced by renal function. Therefore,
the associations between lead dose and uric
acid may be due to the same process causing
inverse associations between lead dose and
renal function in those with the ALAD2 allele.
If this process represents lead-related hyperﬁl-
tration, the associations between lead dose and
uric acid may become positive as this popula-
tion ages and eventually, as in the Normative
Aging Study, be stronger in those with the
ALAD2 allele than in those with the ALAD1-1
genotype. However, several steps are involved
in the renal handling of uric acid, including a
secretion step in the proximal tubule, which is
also thought to be adversely affected by lead.
The fact that effect modification by ALAD
genotype on associations between tibia lead
and uric acid persists after adjustment for renal
function suggests that one or more of the other
renal handling processes for uric acid are
involved. Analysis of our longitudinal data will
be very helpful in understanding these complex
relations.
The potential for uric acid–related nephro-
toxicity must be considered in these associa-
tions, as well. When previously published
models of effect modification by ALAD on
associations between lead dose and renal
function (Weaver et al. 2003b) were also con-
trolled for uric acid, the effect modification
observed remained statistically signiﬁcant (data
not shown), indicating that this effect is not
mediated solely through uric acid. However,
the current analyses do provide further evi-
dence, in addition to our recently published
results (Weaver et al. 2005), that lead dose
increases uric acid in these workers, even after
control for variables that are both confounders
and mediators, such as blood pressure and
renal function.
Polymorphisms of the gene encoding for
the VDR are of interest in lead-exposed
populations because of the importance of the
receptor for calcium absorption and bone
mineralization. These pathways affect lead
absorption from the gastrointestinal tract and
may affect lead storage and/or release from
bone (Onalaja and Claudio 2000). In the
lead workers studied in this report, partici-
pants with the B allele were found to have
signiﬁcantly higher blood, tibia, and DMSA-
chelatable lead than did those with the bb
genotype (Schwartz et al. 2000a). The effect
modiﬁcation of VDR genotype on the associa-
tion of tibia lead and uric acid in participants
who are in the older half of the population
may reflect toxicodynamic differences.
However, conclusions must be tempered by
the fact that this effect is dependent on, at
most, 27 participants with tibia lead levels
> 103 µg Pb/g bone mineral who reduce the
β estimate of the relation between tibia lead
and uric acid in participants with the bb geno-
type. Further, no associations between VDR
genotype and renal outcomes were observed,
nor was consistent effect modification by
VDR on associations between lead measures
and renal outcomes present in this population
(Weaver et al. 2003b). Interestingly, the shape
of the lowess lines for the relations between
tibia lead and uric acid in workers with the
common genotypes (ALAD1-1 and VDR bb;
Figures 2 and 3) suggests differences at higher
tibia lead levels that could reﬂect survivor bias.
We plan to explore this further in longitudinal
analyses.
eNOS catalyzes the transformation of
L-arginine to the vasodilator, nitric oxide
(NO). Animal models of kidney disease indi-
cate that administration of L-arginine results in
decreased renal damage that is thought to be
mediated via increased NO (Klahr 2001). The
functional signiﬁcance of the Glu298Asp poly-
morphism remains uncertain. Some authors
have reported decreased NO with the variant
Asp allele (Noiri et al. 2002; Persu et al. 2002;
Sofowora et al. 2001). However, others have
reported no difference in various functional
measures (Golser et al. 2003; Hoffmann et al.
2005; Li et al. 2004; Moon et al. 2002). If the
Asp allele is ultimately shown to decrease NO,
the variant may confer additional risk in lead
exposure that also decreases NO (Vaziri
2002). In addition, this eNOS polymorphism
may modify lead toxicokinetics. A recent
study of data from the third evaluation of the
lead workers in this report (n = 652) found
that eNOS genotype modified the relation
between patella lead and age; workers with
the Asp allele had higher increases in patella
lead with increasing age than did lead workers
who were homozygous for the Glu allele
(Theppeang et al. 2004). In the population
that is the focus of this report, we found
inconsistent associations of eNOS genotype
with renal function (higher BUN and meas-
ured creatinine clearance in those with the Asp
allele) (Weaver et al. 2003b). Effect modiﬁca-
tion was also noted; longer lead job duration
was associated with higher serum creatinine
and lower calculated creatinine clearance in
participants with the Asp allele and with
higher calculated creatinine clearance in par-
ticipants with the Glu/Glu genotype (Weaver
et al. 2003b). The lower uric acid observed in
those with the Asp allele may indicate that, if
this allele does confer increased renal risk in
lead exposed populations, uric acid does not
contribute further to that risk.
Our data suggest that all three genetic
polymorphisms may affect uric acid in these
lead workers. However, effect modiﬁcation by
ALAD genotype on associations between lead
dose and uric acid was most consistent with
the observed effect modiﬁcation by this geno-
type on associations between lead dose and
renal function. This work also suggests that
effect modification by genotype is present
only in the older half of the population.
However, our ability to explore effect modiﬁ-
cation by genotype in different age groups is
limited by the small number of participants
with the variant alleles in these age-stratiﬁed
models. As a result, even after removal of out-
liers, most data points in the variant groups
are inﬂuential. Longitudinal data analysis will
be useful, particularly in understanding the
inverse associations seen with ALAD.
Weaver et al.
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Figure 3. Added variable plot of the model assessing effect modiﬁcation by VDR genotype on the associa-
tion between tibia lead and uric acid in Korean lead workers ≥ 40.6 years of age (median) (Table 4, panel
2). For each plot, the regression line (dashed line) and the lowess line (solid line) of the partial residual
data points, adjusted for age, sex, BMI, and alcohol use, are overlaid. For ease of interpretation, axes have
been scaled so that the plotted residuals are centered around mean uric acid and tibia lead, rather than
around zero.
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